Macular Degeneration Trial, Recruiting NCT07446582 Sponsor: AI-Spectral Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT07446582
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with AMD:

  • Adults over 40 years of age who have been diagnosed with a specific type of age-related macular degeneration (AMD)
  • People who are able to understand and sign an ethics-approved consent form
  • People who have attended the clinic at least once before
  • People whose previous eye scans show signs of this type of AMD in at least one eye (such as deposits under the retina or changes to the back of the eye)

For healthy volunteers:

  • Adults over 40 years of age who have not been diagnosed with any type of AMD, and whose previous eye scans show no signs of AMD or other eye conditions affecting the retina
  • People who have at least some minimal ability to detect light, which is needed to focus during the eye scan
  • People whose eyes have been reviewed and confirmed as healthy by two independent clinicians

Who may not be able to join:

  • People whose eyes have cloudiness or opacity (such as a significant cataract or cloudy cornea) that would prevent clear eye imaging
  • People with very high levels of short-sightedness (at or beyond -10.00D) or long-sightedness (at or beyond +6.00D) that could affect image quality
  • People with active eye infections, severe eye inflammation, or a recent eye injury
  • People who have had eye surgery (such as cataract, retinal, or glaucoma surgery) within the past 3 months — though injections into the eye for a specific retinal condition may be an exception (confirm with trial site)
  • People with a history of, or current signs of, other retinal conditions (such as diabetic eye disease, retinal vein or artery blockage, or high blood pressure-related eye damage), other than the specific AMD type this trial is studying
  • People who have previously had certain types of eye surgery for retinal detachment or related conditions, as this could affect imaging results
  • People who have difficulty keeping their gaze steady during imaging, including those with advanced involuntary eye movements, a significant lazy eye, or conditions such as dementia that affect concentration
  • People with severe dry eye or other surface eye conditions that could interfere with imaging or cause discomfort during the procedure
  • People with essential tremor (uncontrolled shaking of the head or neck) that would prevent clear imaging
  • People who are unable to understand or who decline to sign the consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 16135816702

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
AI-Spectral
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
5 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assessment of equivalency in sensitivity and specificity of the DeepMSI AI system compared with experienced clinicians for detection of AMD biomarkers.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov